Aldeyra Therapeutics shares are trading lower after the company received FDA complete response letter for ADX-2191 (methotrexate for injection) for primary vitreoretinal lymphoma.
Portfolio Pulse from Benzinga Newsdesk
Aldeyra Therapeutics received an FDA complete response letter for ADX-2191 (methotrexate for injection) for primary vitreoretinal lymphoma, causing its shares to trade lower.
June 21, 2023 | 2:19 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Aldeyra Therapeutics' stock price is trading lower due to the FDA complete response letter for ADX-2191.
The FDA complete response letter indicates that the agency has concerns or requires additional information before approving the drug. This news negatively impacts Aldeyra Therapeutics' stock price as it delays the potential approval and revenue generation from ADX-2191.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100